{
    "symbol": "ELDN",
    "quarter": 4,
    "year": 2022,
    "date": "2023-03-30 20:28:05",
    "content": " Our rationale was based on the significant existing preclinical data from both tegoprubart, our anti-CD40 ligand antibody and historical anti-CD40 ligand antibodies demonstrating the class's potential in organ transplantation combined with a large potential size of the transplant market, a clear regulatory path that also provides for potential upside using kidney function or another predictive endpoint and the concentration of organ transplantation in the United States across a relatively limited number of hospitals, thus making it possible for smaller sized biotech to tackle from a sales and marketing perspective."
}